Compare Panacea Biotech with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AJANTA PHARMA - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AJANTA PHARMA PANACEA BIOTECH/
AJANTA PHARMA
 
P/E (TTM) x 11.7 21.4 54.5% View Chart
P/BV x 2.8 3.8 74.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PANACEA BIOTECH   AJANTA PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
AJANTA PHARMA
Mar-19
PANACEA BIOTECH/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3641,422 25.6%   
Low Rs129898 14.4%   
Sales per share (Unadj.) Rs96.8233.5 41.4%  
Earnings per share (Unadj.) Rs-12.444.0 -28.2%  
Cash flow per share (Unadj.) Rs-2.952.2 -5.5%  
Dividends per share (Unadj.) Rs09.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs50.4255.1 19.8%  
Shares outstanding (eoy) m61.2588.02 69.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.55.0 51.3%   
Avg P/E ratio x-19.926.4 -75.3%  
P/CF ratio (eoy) x-86.422.2 -388.7%  
Price / Book Value ratio x4.94.5 107.6%  
Dividend payout %020.5 0.0%   
Avg Mkt Cap Rs m15,101102,081 14.8%   
No. of employees `0002.56.8 36.3%   
Total wages/salary Rs m1,5164,307 35.2%   
Avg. sales/employee Rs Th2,401.93,022.6 79.5%   
Avg. wages/employee Rs Th614.2633.4 97.0%   
Avg. net profit/employee Rs Th-307.9569.1 -54.1%   
INCOME DATA
Net Sales Rs m5,92820,554 28.8%  
Other income Rs m82211 39.0%   
Total revenues Rs m6,01020,765 28.9%   
Gross profit Rs m8455,664 14.9%  
Depreciation Rs m585721 81.2%   
Interest Rs m1,00612 8,670.7%   
Profit before tax Rs m-6645,143 -12.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m991,273 7.7%   
Profit after tax Rs m-7603,870 -19.6%  
Gross profit margin %14.327.6 51.7%  
Effective tax rate %-14.924.8 -60.0%   
Net profit margin %-12.818.8 -68.1%  
BALANCE SHEET DATA
Current assets Rs m5,60311,812 47.4%   
Current liabilities Rs m6,9103,776 183.0%   
Net working cap to sales %-22.039.1 -56.4%  
Current ratio x0.83.1 25.9%  
Inventory Days Days20677 266.0%  
Debtors Days Days8482 102.6%  
Net fixed assets Rs m9,94114,398 69.0%   
Share capital Rs m61175 34.9%   
"Free" reserves Rs m3,02622,277 13.6%   
Net worth Rs m3,08722,452 13.7%   
Long term debt Rs m5,7077 86,471.2%   
Total assets Rs m16,07626,962 59.6%  
Interest coverage x0.3444.3 0.1%   
Debt to equity ratio x1.80 628,935.3%  
Sales to assets ratio x0.40.8 48.4%   
Return on assets %1.514.4 10.6%  
Return on equity %-24.617.2 -142.8%  
Return on capital %3.923.0 17.1%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60010,682 15.0%   
Fx outflow Rs m1,1312,102 53.8%   
Net fx Rs m4698,580 5.5%   
CASH FLOW
From Operations Rs m1,1803,748 31.5%  
From Investments Rs m553-2,228 -24.8%  
From Financial Activity Rs m-1,644-1,475 111.5%  
Net Cashflow Rs m9045 198.5%  

Share Holding

Indian Promoters % 74.5 73.8 100.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 1.6 38.7%  
FIIs % 1.3 7.6 17.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.0 138.8%  
Shareholders   10,259 20,968 48.9%  
Pledged promoter(s) holding % 35.1 4.4 798.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 93 Points Higher; Oil & Gas and Realty Stocks Witness Buying(Closing)

Indian share markets traded on a volatile note throughout the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the oil & gas sector.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 16, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS